MedTrace Logo

Denosumab for Smoldering Multiple Myeloma

NCT03839459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-01-28

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

Denosumab

120mg of Denosumab will be administered subcutaneously once every 4 weeks

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University of Rochester

    lead OTHER

Principal Investigators

  • Brea Lipe · University of Rochester Wilmot Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-19
Primary Completion
2022-09-16
Completion
2025-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03839459 on ClinicalTrials.gov